VANCOUVER, June 14 /PRNewswire/ - iCo Therapeutics Inc. announced today
that Dr. Philip Rosenfeld has joined iCo's strategic advisory team. Dr.
Rosenfeld is Professor of Ophthalmology at the world-renowned Bascom Palmer
Eye Institute at the University of Miami, Miller School of Medicine.
"Dr. Rosenfeld has been involved in the clinical testing of virtually
every medical treatment for age-related macular degeneration (AMD) and was
the first to demonstrate the usefulness of Avastin in treating the
disease," said Andrew Rae, iCo President and CEO. "Dr. Rosenfeld's vision
and pioneering efforts with Avastin have led to a paradigm shift in the way
AMD is treated today. We are extremely pleased to have him join our
strategic advisory board and help guide the acquisition and clinical
development of our products."
Dr. Rosenfeld's chief research interests are in the diagnosis,
treatment and genetics of macular diseases. He is at the forefront of
medical testing having spent the past decade seeking effective therapies
for AMD. He is currently Principal Investigator of nine clinical trials for
AMD. In May 2005, Dr. Rosenfeld was the first to perform an intravitreal
injection of Avastin - a drug approved to treat colon cancer - for the
treatment of wet AMD. By injecting a small amount of the drug into the eyes
of patients with wet AMD, Dr. Rosenfeld showed that Avastin not only halted
the progression of neovascularization in these patients, but also resulted
in an improvement in vision in many of the patients. These findings have
since been put into practice by physicians around the world.
Dr. Rosenfeld received a Medical Degree and PhD from the Johns Hopkins
University School of Medicine in Baltimore. He completed a residency at
Harvard's Massachusetts Eye and Ear Infirmary and fellowships at both the
Department of Ophthalmology at Harvard University and the Bascom Palmer Eye
Institute at the University of Miami, Miller School of Medicine.
iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology
company focused on developing pre-existing drugs for a range of new
conditions affecting isolated biological environments-areas such as the
eye, spinal cord, or joints-where locally-administered application of these
therapies would have minimal systemic distribution and fewer safety issues.
For more information, visit the company website at:
Business Development Contact: Finance/Investor Contact:
Dr. John Clement, CT&DO Mr. John Meekison, CFO
Amanda Smith, Principal, Smith Biotech
SOURCE iCo Therapeutics Inc.